Cartalax

Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, with research focus on cartilage and joint tissue. It is studied as a tissue-specific regulator for chondrocyte function and is sold strictly for laboratory use.

Cartalax is the joint-and-cartilage entry in the Khavinson bioregulator catalog. Cartilage is notoriously hard to repair — it has poor blood supply, and damaged cartilage rarely fully regenerates. Cartalax is studied as a small peptide signal that supports chondrocyte (cartilage cell) function and tissue maintenance. It shows up in longevity and joint-health research discussions alongside BPC-157 and TB-500.

Like other Khavinson tripeptides, Cartalax is proposed to enter cells and modulate transcription of cartilage-specific genes. In animal and cell-culture work, exposure to Cartalax has been associated with maintained chondrocyte viability and slowed markers of cartilage degeneration. Mechanistic data is less comprehensive than for larger, mainstream peptides.

• •Chondrocyte viability in aging cartilage
• •Osteoarthritis models
• •Cartilage regeneration research
• •Khavinson bioregulator family comparative studies
• •Joint tissue gene expression

Cartalax is a deep-cut peptide referenced mostly on longevity forums and by users specifically interested in joint health beyond the BPC-157/TB-500 mainstream. Conversations are small but engaged, often citing Russian literature and proposing combination protocols.

“A small tissue switch aimed at cartilage cells.”

Cartalax is commonly combined in joint-health discussions with BPC-157 (for soft-tissue repair) and TB-500 (for systemic recovery). Bioregulator stacks may pair it with Cortagen, Cardiogen, or Epitalon for whole-system longevity research.

Cartalax is a Khavinson bioregulator tripeptide studied for chondrocyte function and cartilage tissue maintenance. It is part of the tissue-specific bioregulator family and sold for laboratory research only.